Ophthal-360 is an AI technology for autonomous detection of Diabetic Retinopathy (DR), enabling efficient and fast screenings for signs of Diabetic Retinopathy in both clinical and retail settings.
Before you continue reading about the Ophthal-360, it would be a great idea to familiarize yourself with Diabetic Retinopathy. Read more further below.
Ophthal-360 Real-time Quality Assessment
Ophthal-360 verifies the quality of submitted photos in real-time to ensure they can be read.
Diabetic Retinopathy Severity Grading
Want to try ophthal-360?
Ophthal-360 can be integrated with your clinical workflow to enable automated DR screening.
Frequently asked questions
Ophthal-360 is an AI-based technology that autonomously detects mild to moderate (mtmDR) and vision-threatening diabetic retinopathy (vtDR) in the eyes of adults diagnosed with diabetes mellitus and who have not been previously diagnosed. The purpose of the Ophthal-360 is to make it accessible to perform and receive diabetic retinopathy screenings.
The Ophthal-360 system autonomously analyzes a patient’s retinal images taken using a fundus camera, robustly detects lesions, and delivers a report in under 10 seconds on the same day.
The Ophthal-360 AI eye screening is primarily cloud-based and installed on most Windows PCs with internet access. Therefore, no additional software is required.